Table 3 Comparison of responders and non-responders, for age, sex, spondyloarthritis diagnosis and pharmacological treatment. Legend: Both responders and non-responders may have received more than one diagnosis or pharmacological treatment during the respective time frame
Responders (n = 2785)a | Non-responders (n = 2986)a | p-value | |
|---|---|---|---|
Demographics | |||
Age, median (Q1, Q3) | 57 (45, 66) | 53 (41, 66) | <0.001 |
Sex, n women (%) | 1494 (49) | 1551 (51) | 0.290 |
Diagnoses, n (%) | |||
Ankylosing spondylitis | 744 (27) | 679 (23) | 0.001 |
Psoriatic arthritis | 1285 (46) | 944 (32) | <0.001 |
Undifferentiated SpA | 411 (15) | 300 (10) | <0.001 |
Sacroiliitis | 157 (6) | 209 (7) | 0.035 |
Reactive arthritis | 359 (13) | 924 (31) | <0.001 |
IBD-associated arthritis | 66 (2) | 65 (2) | 0.659 |
Spine enthesiopathy | 13 (1) | 12 (0) | 0.842 |
Psoriatic spondylitis | 20 (1) | 19 (1) | 0.750 |
Treatment, n (%) | |||
Methotrexate | 936 (34) | 538 (18) | <0.001 |
Sulphasalazine | 297 (11) | 159 (5) | <0.001 |
Etanercept | 323 (12) | 153 (5) | <0.001 |
Adalimumab | 168 (6) | 94 (3) | <0.001 |